Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients
NCT03127020
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
9
Enrollment
INDUSTRY
Sponsor class
Conditions
Lymphoma
Non-Hodgkin Lymphoma
Interventions
DRUG:
PQR309
Sponsor
PIQUR Therapeutics AG
Collaborators
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]